Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients.

Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann MA, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, Kaeuferle T, Rohlfs M, Binder V, Klein C, Feuchtinger T.

Leukemia. 2020 Mar 13. doi: 10.1038/s41375-020-0793-1. [Epub ahead of print]


Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.

Willier S, Cabanillas Stanchi KM, von Have M, Binder V, Blaeschke F, Feucht J, Feuchtinger T, Döring M.

BMC Cancer. 2019 Nov 15;19(1):1118. doi: 10.1186/s12885-019-6252-6.


Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.

Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B, Kaeuferle T, Feucht J, Willier S, Handgretinger R, StevanoviĆ S, Lang P, Feuchtinger T.

Cytotherapy. 2019 Sep;21(9):973-986. doi: 10.1016/j.jcyt.2019.06.009. Epub 2019 Jul 25.


Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.

Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T.

J Hematol Oncol. 2019 Feb 6;12(1):13. doi: 10.1186/s13045-019-0701-1. Review.


Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.

Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T.

Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066. doi: 10.1007/s00262-018-2155-7. Epub 2018 Mar 31.


The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth.

Grunewald TG, Willier S, Janik D, Unland R, Reiss C, Prazeres da Costa O, Buch T, Dirksen U, Richter GH, Neff F, Burdach S, Butt E.

Biol Cell. 2013 Nov;105(11):535-47. doi: 10.1111/boc.201300041. Epub 2013 Sep 18.


Defining the role of TRIP6 in cell physiology and cancer.

Willier S, Butt E, Richter GH, Burdach S, Grunewald TG.

Biol Cell. 2011 Dec 1;103(12):573-91. doi: 10.1042/BC20110077. Review.


Supplemental Content

Loading ...
Support Center